Frontlight ResearchEarly access
Active, not recruitingPhase 3
Dronabinol After Arthroscopic Surgery
Key facts
- Who runs it
- Northwestern University
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 30 people, planned
- Started
- 28 Jun 2022
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Dronabinol
- Placebo
- Record updated
- 25 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- Age 18 years or older
- Patient who will undergo arthroscopic surgery of the knee including, but not limited to,; Meniscectomy; Synovectomy; Chondroplasty; Loose body removal
Who cannot take part
- Revision surgery
- Open surgery
- Comorbidities preventing surgery
- Patients taking any of the following drugs or supplements; Anticholinergic agents; Benzodiazepines; Central nervous system depressants; Droperidol; Hydroxyzine; Levomepromazine or methotrimeprazine; Monoamine oxidase inhibitors; Ritonavir; Selective serotonin reuptake inhibitors; Sympathomimetics; St. John's Wort
- Current diagnosed alcohol or drug abuse
- Patients who cannot or will not abide by the medication restrictions listed below; Medication restrictions
- Participants should not drink alcohol or take other drugs while taking the study drug or hydrocodone/acetaminophen
- Patients with an allergy to any of the study drugs
- Patients with a history of mania, depression, or schizophrenia
- Patients under age 18 years
- Patients who cannot provide consent
- Patients who are pregnant, breast feeding, or are trying to become pregnant during the study period
- Patient who are lactose-intolerant
- Participants must agree to abstain from using recreational or medical marijuana products or cannabidiol (CBD) in any form during the treatment period
Where in United States
- Northwestern University Feinberg School of MedicineChicago, United States
About the trial
What the trial wants to find out
The purpose of the proposed study is to evaluate the efficacy of dronabinol for postoperative pain after arthroscopic surgery of the knee. The investigators hypothesize that dronabinol will relieve pain, reduce opioid consumption and will result in few negative side effects. If this pilot study shows promising results the investigators will expand the trial to include additional arthroscopic surgeries (hip, shoulder) and other types of orthopaedic surgery.
The 2 groups in the trial
- DronabinolTreatment being tested
Patients will received dronabinol (5mg) twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
- PlaceboPlacebo, for comparison
Patients will received placebo twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Dronabinol for the Treatment of Postoperative Pain After Arthroscopic Surgery: a Pilot Randomized Trial
- Record updated
- 25 September 2026